Prostox - learn about whether radiation will cause problems
The Prostox test evaluates whether or not you will have side effects from having different types of radiation.
PROSTOX works not just for first time radiation but for recurrence and maybe even radioligand therapy like Pluvicto. By analyzing your unique genetics, you can make smarter, more informed decisions to avoid side effects and safeguard your quality of life for years to come.
PROSTOX Standard (previously PROSTOX CFRT+) predicts late grade ≥2 toxicity from conventionally fractionated (CFRT) or moderately hypofractionated (MHFRT) radiation therapy for patients with localized prostate cancer.
Together with PROSTOX Ultra, which is already available for patients considering stereotactic body radiation therapy (SBRT), the PROSTOX portfolio now provides risk assessment across a broader range of external beam radiation therapy (EBRT) types.
We'll discuss the updates and other patient concerns such as insurance coverage and questions to bring to your doctors.
Join us April 27th, 2026 for a special presentation by test developer, Dr. Joanne Weidhaas, 7:00 - 7:55 pm Eastern - Dr. Weidhaas Presentation in the AnCan Barniskis Room
You do need to Goto meeting installed in order to attend this event
Just put Barniskis for the session to join
Interested in more discussions like this? Go to the Prostate Cancer Support Group.
Connect

@climateguy
Thank you very much.
Here is a link to the first Prostox Presentation at Ancan.Org done by The developer of the test.
https://ancan.org/
@quaddick Hi Quaddick! Like you, my husband is one of the "rare" 1-2% who Prostox scored "High Risk" for both SBRT and CFRT/IMRT.
Last week he successfully underwent TULSA-Pro. Six days later he got his catheter out! ....Thank you Prostox.
-
Like -
Helpful -
Hug
1 Reaction